Graffinity, Serono link for drug discovery

April 4, 2003 — Graffinity Pharmaceuticals AG is teaming up with Serono SA to discover new drugs using chemical microarrays, according to a news release.

null

Graffinity, a German microarray drug discovery platform developer, will apply its Rapid Affinity Instructed Structure Evolution (RAISE) technology along with Swiss-based Serono’s target proteins to find new compounds for diseases related to immunology and reproductive health.

null

Under terms of the deal, Serono will have the option to fully own any structures generated by Graffinity. Graffinity will retain the right to develop the remaining compounds, will receive fees based on certain milestones and could potentially receive royalties on any products Serono commercializes as part of the collaboration, the release said.

POST A COMMENT

Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.